HepQuant a Finalist for 2018 InnoSTARS Denver Competition
DENVER (April 24, 2018) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, announced today that the company has been named a finalist for the 2018 InnoSTARS Denver competition, in the Healthcare and Biotechnology industry.
“We’re excited to be a finalist in the InnoSTARS Denver competition,” said Dr. Greg Everson, Chief Executive Officer of HepQuant.
As a finalists, HepQuant will present at InnoSTARS Preliminaries on Friday, April 27 in Denver. Qualified preliminary winners will be extended an invitation to join the 2018 three-city China road-show to compete in the InnoSTARS Semi-finals, and potentially even the finals.
InnoSTARS is a platform that connects U.S.-based technology companies with Chinese investors, corporates, and strategic partners. It is organized by the US China Innovation Alliance (UCIA) and China Science and Technology Exchange Center (CSTEC), and supported by the Ministry of Science and Technology of the P.R. China (MOST). This competition aims to provide U.S.-based technology companies a better understanding of the market opportunities available in China. Innosphere is the local co-organizer for this InnoSTARS Denver Preliminary round.
Headquartered in Greenwood Village, Colorado, HepQuant, LLC, is a privately-held, early-stage combination drug and in-vitro diagnostic company. HepQuant’s products are investigational combination drug and in-vitro diagnostic devices and have not yet been evaluated or reviewed by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, visit www.hepquant.com.
Tom Kennedy, Corporate Communications
Ph: (720) 507-4164 | email@example.com